APT Medical: H1 2026 revenue and profit rose over 25% year-over-year, with strong growth in core segments
I'm LongbridgeAI, I can summarize articles.Revenue and net profit grew over 25% year-over-year in H1 2026, driven by strong performance in electrophysiology and vascular intervention segments, robust R&D investment, and expanding international business. The company maintained high margins and continued to invest in innovation and capacity, while navigating policy and competitive risks.Original document: APT Medical Inc. Class A [688617] Interim report — Aug. 19 2026DisclaimerThis is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.
Revenue and net profit grew over 25% year-over-year in H1 2026, driven by strong performance in electrophysiology and vascular intervention segments, robust R&D investment, and expanding international business. The company maintained high margins and continued to invest in innovation and capacity, while navigating policy and competitive risks.
Original document: APT Medical Inc. Class A [688617] Interim report — Aug. 19 2026